**Cholesterol Management Best Practices: Team-Based Care (4.14.25)**

May 5, 2025 – December 31, 2025

**Target Audience**

Specialties – Emergency Medicine, Family Medicine, Medicine, Neurology, Obstetrics & Gynecology, Radiological Sciences, Other

**Activity Objectives**

1 Apply Key Thresholds and Risk Assessment Strategies: Discuss evidence-based approaches to cholesterol management, emphasizing treatment thresholds, risk assessment, and team-based strategies aligned with current clinical guidelines

2 Highlight the Role of Team-Based Care: Illustrate how interdisciplinary collaboration (physicians, pharmacists, dietitians, etc.) enhances cholesterol management outcomes

3 Define Team Member Responsibilities: Clarify the specific roles and contributions of each team member in managing patients with hyperlipidemia

4 Identify Gaps and Opportunities: Evaluate current practices and identify areas for improvement in cholesterol management workflows

5 Highlight successful case studies or programs that demonstrate effective cholesterol control through collaborative care. Team-based care improves access, adherence, lifestyle modification, and therapeutic intensification

**Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and UC Berkeley.  The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Enduring Material for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.



A close-up of a sign

AI-generated content may be incorrect.

ABIM
CME
MOC
Accredited

ABIM
CME
MOC
Accredited

CME for
ABPath CC

Part 2
MOC
The American Board of Pediatrics

**MOC Statement(s)**

ABIM
CME
MOC
AccreditedSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ABMS

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sarah Epstein, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Hattie Hanley, Other | Course Director | Nothing to disclose - 10/23/2024 |
| Nathan D. Wong, PhD, MPH | Planning Commitee Member | Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Consulting Fee-Heart Lung|Grant or research support-Amgen, Inc.|Speakers Bureau-Novartis Corporation Pharmaceuticals - 01/06/2025 |
| Jan Hirsch, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Cindy Giambrone, PharmD | Planning Commitee Member | Stocks or stock options, excluding diversified mutual funds-Sanofi S.A.|Stocks or stock options, excluding diversified mutual funds-Abbott (Any division) - 02/12/2025 |
| William Bommer, MD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Eveline Stock, MD | Faculty | Grant or research support-Novartis Corporation Pharmaceuticals - 04/23/2025 |
| Angela M Fong, RD | Faculty | Nothing to disclose - 04/28/2025 |
| Paige Hutchison, PharmD | Faculty | Nothing to disclose - 05/01/2025 |

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.